BMEA Projected Dividend Yield
Biomea Fusion Inc ( NASDAQ : BMEA )Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. Co. is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. 21 YEAR PERFORMANCE RESULTS |
BMEA Dividend History Detail BMEA Dividend News BMEA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |